Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

0.9999 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.9999
Bid (Size) 0.3961 (2)
Ask (Size) 1.270 (2)
Prev. Close 0.9999
Today's Range 0.9999 - 0.9999
52wk Range 0.6488 - 3.595
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Upcoming $1.6M Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Advancing its DehydraTECH(TM) Technology, Having Demonstrated its Potential Across Multiple Areas of Application
Via Investor Brand Network

Performance

YTD
-60.79%
-60.79%
1 Month
-0.01%
-0.01%
3 Month
+33.32%
+33.32%
6 Month
-62.78%
-62.78%
1 Year
-60.79%
-60.79%

More News

Read More
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Studies to Examine DehydraTECH(TM)-Powered GLP-1 Drugs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Studies to Examine DehydraTECH(TM)-Powered GLP-1 Drugs
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) to Demonstrate DehydraTECH-CBD Benefits in Upcoming Investigational New Drug Application Submission
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) New Subsidiary Maximizing Patented DehydraTECH(TM) in Various Markets
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) is On Track for IND Application with the FDA for its Planned U.S. Phase 1b Hypertension Clinical Trial
Via Investor Brand Network
Exposures Product Safety
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Investigational Research Programs Position the Company for Important Partnership Opportunities and Growth
Via Investor Brand Network
CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) ‘Strategically Important’ Patent Grants Protection in One of World’s Leading Oral Nicotine Markets
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes What Is Considered One Of America’s Most Serious Health Problems
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Update on IND Application Progress
Via Investor Brand Network
Topics Intellectual Property Supply Chain
Exposures Intellectual Property Product Safety Supply Chain
Lexaria Provides Update on Investigational New Drug Application Progress
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Launching IND Program on DehydraTECH-CBD for Hypertension
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Launching IND Program on DehydraTECH-CBD for Hypertension
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Affirms Product Superiority in Its 2023 Human Oral Nicotine Study, NIC-H22-1
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Affirms Product Superiority in Its 2023 Human Oral Nicotine Study, NIC-H22-1
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Strategic Updates Concerning Patented DehydraTECH(TM) Technology
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Intent for Human Clinical Study for Diabetes and Weight Loss Following Positive DehydraTECH(TM)-CBD Results in Animals
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Results from Human Oral Nicotine Study Evaluating DehydraTECH(TM)-Nicotine
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Results from Human Oral Nicotine Study Evaluating DehydraTECH(TM)-Nicotine
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates ‘Strategically Important’ New Patent Granted in the US
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates ‘Strategically Important’ New Patent Granted in the US
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.